Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. (2014)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2014-005094
PubMed Identifier: 25079928
Publication URI: http://europepmc.org/abstract/MED/25079928
Type: Journal Article/Review
Volume: 4
Parent Publication: BMJ open
Issue: 7
ISSN: 2044-6055